Slide 1: Partnering and Investor Presentation September 2022
@& Dimerix (ASX:DXB) r Partnering and me \ Investor Presentation SY SS, Y September 2022 ~ f Authorised for lodgment by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Lead Drug Candidate Oma Sia Ready DMxX-200 Strong Pipeline Demonstr
Slide 4: ACTION3 FSGS study part 1 recruitment status
OQ ACTICING - Study part 1 recruitment status FSGS CLINICAL STUDY Patients recruited*: 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Estimated * On track to complete Part 1 recruitment and dosing Q4 2022 ¢ Part 1 data outcome anticipated mid-2023 || i Northern hemisphere summer holiday # Start up acti
Slide 5: Share price and shareholders
For personal use only Share price Shareholders1 14% 6% 5% 75%
Slide 6: Development pipeline
Development pipeline Program Indication Preclinical Phase1 Phase2 Phase3 Key milestones Focal Segmental Glomerular Sclerosis Gi» Phase 2a demonstrated encouraging efficacy & safety’; Phase 3 underway (FSGS) across “70 sites globally2, Part 1 completion anticipated mid-23? Phase 2 demonstrated promis
Slide 7: Glomerulosclerosis
Glomerulosclerosis Inside a healthy kidney Inside a damaged kidney | Focal Segmenta | Focal =some Segmental = sections blood blood filter filter Sclerosis = are scarred urine cy oe \ ~ | A ) . $ + % ° = Protein Glomerulo = of the kidney filtering units Protein in the urine = proteinuria) * A rare di
Slide 8: FSGS: unmet need and market potential
| FSGS: unmet need and market potential No therapies yet approved for FS “40,000 50% ~1000 easiata the US are of patients with FSGS FSGS patients in US as acer with FSGS! will progress to kidney i receive a kidney 9g failure? | transplant each year? / ‘ cost of average orphan an * nd drug per month
Slide 9: Renal disease landscape
Renal disease landscape ‘A squeaky wheel waiting for grease: 50 years of kidney disease management in the US” Historical lack of incentives and public policy have |contributed to high costs and| poor health outcomes for renal patients! 2018: workshops and regulatory acceptance of surrogate end point
Slide 10: Policy change: renal disease healthcare economic burden
Policy change: renal disease healthcare economic burden “40 million adults have kidney / disease (“15% of the adult population) in the US in 20211 2019 White House executive order issued: incentives for providers to delay patient progression to renal failure 2 @w Dimerix US$88 billion estimated tota
Slide 11: For personal use only
2,500.00 For personal use only REG 1x P3 Ren Reg 1x P3 Ren 2,000.00 WW 1x P1 Ren WW 1x P2 Mul 1,500.00 CTRY 1x P3 Ren CTRY 1x P2 Ren 1,000.00 WW 1x P3 Ren Reg 1x Pre Ren 500.00 Reg 1x Pre Ren WW 1x P1 Ren 0.00 Jan-20 Apr-20 Aug-20 Nov-20 Feb-21 Jun-21 Sep-21 Dec-21
Slide 12: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease ATIR — blocked by angiotensin receptor blocker (ARB) CCR2 —CCR2 is the receptor for MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys? 1 Hyperfiltration of and hypertension within blood vessels of the glomerul
Slide 13: Phase 3 studies investigating FSGS treatments
Phase 3 studies investigating FSGS treatments No therapies yet approved specifically for FSGS Drug candidate Primary interim (accelerated approval) endpoint ACTION3" DMX-200 CCR2 inhibitor Placebo Percent change in uPCR and eGFR slope at week 35 Dual Proportion of patients achieving uPCR < 1.5g/g an
Slide 14: Kidney Disease Development Overview
Kidney Disease Development Overview
Slide 15: DMX-200 working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Small molecule Clear Development Path [Easy and convenient dosing Extensive regulatory engagement New Chemical Entity
Slide 16: DMX-200 clinical studies
For personal use only Phase 1 study (DMX-200-101) Phase 2a study (DMX-200-201) Phase 2a study (DMX-200-202) Phase 2 study (DMX-200-203) • Healthy volunteers • Chronic Kidney Disease • Focal Segmental • Diabetic kidney disease ➢ Pharmacokinetic, ➢ Safety and tolerability Glomerulosclerosis ➢ Efficacy
Slide 17: DMX-200 treatment group met primary and secondary endpoints
DMX-200 treatment group met primary and secondary endpoints * 86% of patients demonstrated reduced oe . . proteinuria on DMX-200 +No safety concerns — _ Average reduction in proteinuria after 16 weeks versus placebo oe soo opment risk treatment on DMX-200 versus placebo compared . , . S compares P :
Slide 18: ACTION3 FSGS Phase 3 study design
OQ ACTI 3N3 - FSGS phase 3 study design FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 1 0 35 104 ' ! c i = ca 2 DMX-200 @ rt = & 21] —€ 5 Ff io] ®
Slide 19: ACTION3 FSGS Phase 3 study locations
O ACTICING - FSGS phase 3 study locations — Part 1 FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Global study recruiting across “70 sites: ° Australasia: 9 sites ° Asia: 9 sites ° Europe 18 s
Slide 20: ACTION3 study part 1 recruitment status
OQ ACTICING - Study part 1 recruitment status FSGS CLINICAL STUDY Patients recruited*: 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Estimated * On track to complete Part 1 recruitment and dosing Q4 2022 ¢ Part 1 data outcome anticipated mid-2023 || i Northern hemisphere summer holiday # Start up acti
Slide 21: DMX-200 intellectual property and exclusivity
DMX-200 Intellectual property and exclusivity 10 years 20424 2 03 3 Orphan exclusivity in Method of Use Method of Use US/Europe2 Granted? ny CCR2 inhibitor with y ARB for any kidney disease Global application = any CCR2 antagonist with any endothelin A receptor for any disease Further applications i
Slide 22: Additional longer term propositions
Additional longer term propositions
Slide 23: Additional asset value propositions
Additional asset value propositions Longer term opportunities Diversifying DMX-200 risk and Diabetic Kidney potential j sources of Disease revenue Addressable market US$11 billion’ Key driver is the rise in diabetes global incidence DMX-700 Chronic Obstructive Pulmonary Disease Global COPD treatment
Slide 24: COPD efficacy
CO Pp D effi Ca cy 150- ** 80% reduction in lung injury Es (p<0.01) oe DMX-700 shows significant efficacy with 80% reduction in 23 100-4 lung injury of COPD (p<0.01, n=6) 3 ra oOo. Oo The clinical design underway s = 50-4 uw kk COPD is the third-leading cause of death in the world, ao causing 3.23 m
Slide 25: For personal use only
For personal use only
Slide 26: For personal use only
For personal use only ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑
Slide 27: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Advancing three Phase 3 opportunities Well positioned to deliver against strategic plan Dimerix HQ
Slide 28: Appendix
a@)\_ or personal use ‘= 7 _4 Dimerix, Appendix
Slide 29: Board of Directors
For personal use only James Williams Nina Webster Hugh Alsop Sonia Poli PhD, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director iCeutica, Yuuwa, AdAlta Wyeth (Pfizer), Acrux, Immuron, Mayne Pharma, Acrux, Hatchtech,
Slide 30: Management team
For personal use only Nina Webster Hamish George Ash Soman Robert Shepherd Bronwyn Pollock PhD, MBA, M.IP.Law BCom, CA, GIA(Cert) MBBS MRCP(UK) MBA PhD BSc (Hons), MBA CEO & Managing Director CFO & Company Secretary Chief Medical Officer VP R & D VP Product Development Wyeth (Pfizer), Acrux, Immuron
Slide 31: Scientific advisory board
For personal use only Professor Hiddo Heerspink Professor Alessia Fornoni Professor Jonathan Barratt Associate Professor Lesley Inker Dr Muh Geot Wong PhD MD, PhD, FASN MD, PhD, FRCP MD, MS, FRCPC MBBS, PhD, FRCP Chairman Member Member Member Member
Slide 32: AT1R and CCR2 form functional heteromers
AT1R and CCR2 form functional heteromers Unique pharmacology of AT1R/CCR2 heteromer Proprietary discovery platform (Receptor-HIT) identified: LE Cc wy Ww ¥ * Formation of AT1R and CCR2 heteromers; a & MC ee as present * Novel pharmacology (potentiation of 3 2 signaling) 2 3 * Dual antagonism require
Slide 33: For personal use only
For personal use only • Proposed non-clinical package suitability for NDA confirmed with FDA f
Slide 34: For personal use only
For personal use only • • • • • • •
Slide 35: Phase 2a DMX-200-202 (ACTION for FSGS)
For personal use only Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Focal Segmental Glomerulosclerosis who are Receiving an ARB • Primary endpoint: safety; Secondary endpo
Slide 36: Phase 2a trial safety
Phase 2a trial safety Patients wi treatment Gia aeWelse event * Consistently safe and well tolerated in both uring study period DMX-200 Placebo healthy volunteers and renal patients across all Any 7 6 studies to date (total of 95 patients dosed) Drug-related (0) 10) Serious " 0 Leading to dose inter
Slide 37: DMX-200 inflammatory biomarker
DMX-200 inflammatory biomarker Average baseline MCP-1 versus Change in MCP-1 over time on average baseline proteinuria DMX-200 versus placebo = 600 50 2 . — 3 = 400 2 % 8 E 3 2 -37%" -39%" @ 200 ae 3% = g -= On placebo é °. Pi 3 -& Onactive 0 200 400 600 800 1000 Baseline PCR (mg/mmol) 0 5 40 15 Tim
Slide 38: PCR reduction
For personal use only • PCR reduction